8-K: Rapport Therapeutics Announces Positive Financial Results and Clinical Trial Progress for 2024

Rapport Therapeutics reports promising financial results for 2024, highlighted by a strong cash position and advancements in their RAP-219 clinical trials for neurological disorders.

Summary

• Rapport Therapeutics announced its financial results and business highlights for the year ended December 31, 2024.
• The company's RAP-219 Phase 2a trial in patients with refractory focal epilepsy is progressing as planned, with topline results expected in the third quarter of 2025.
• Rapport anticipates initiating a Phase 2a trial in bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027.
• The company ended the year with $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026.
• Net loss for the full year 2024 was $78.3 million, compared to a net loss of $34.8 million for the full year 2023.
• Research and Development (R&D) expense for the full year 2024 was $60.9 million, compared to $28.0 million for the full year 2023.
• General and Administrative (G&A) expense for the full year 2024 was $22.1 million, compared to $8.2 million for the full year 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical trial progress and a strong cash position. However, the increased net loss and the clinical hold on the DPNP trial introduce some uncertainty.

Positives

• RAP-219 demonstrated neuroanatomical specificity and favorable tolerability in PET and MAD-2 trials.
• The Phase 2a trial for refractory focal epilepsy is progressing as planned with topline results expected in Q3 2025.
• The company has a strong cash position of $305.3 million, expected to fund operations through the end of 2026.
• Jeffrey Sevigny, M.D., a recognized leader in drug development, was appointed as chief medical officer.

Negatives

• The FDA placed a clinical hold on the IND for the Phase 2a trial of RAP-219 for the treatment of DPNP, requiring additional information and protocol design amendments.
• Net loss increased to $78.3 million for the full year 2024, compared to $34.8 million for the full year 2023.
• R&D expenses increased to $60.9 million for the full year 2024, compared to $28.0 million for the full year 2023.
• G&A expenses increased to $22.1 million for the full year 2024, compared to $8.2 million for the full year 2023.

Risks

• The company's ability to resolve the clinical hold with the FDA for the DPNP trial is uncertain.
• Clinical trial results may not be favorable.
• The company may need to raise additional capital in the future.
• Regulatory approvals may not be obtained on the expected timeline, if at all.
• The company depends on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved.

Future Outlook

Rapport Therapeutics expects its current cash position to fund operations through the end of 2026 and anticipates advancing its clinical programs for RAP-219 in focal epilepsy, bipolar mania, and peripheral neuropathic pain.

Management Comments

• Abraham N. Ceesay, CEO of Rapport, stated that the PET and MAD-2 trial results demonstrated neuroanatomical specificity and favorable tolerability, reinforcing the belief in RAP-219's differentiated precision profile.
• Abraham N. Ceesay, CEO of Rapport, stated that the company is committed to the pipeline-within-a-product strategy for RAP-219.

Industry Context

Rapport Therapeutics is operating in the competitive biotechnology industry, focusing on neurological and psychiatric disorders. The company's approach of developing small molecule precision medicines targeting RAPs is a differentiated strategy compared to traditional neuroscience drug discovery.

Comparison to Industry Standards

• Many companies such as Biohaven, Cerevel Therapeutics, and Karuna Therapeutics are also developing novel therapies for neurological and psychiatric disorders.
• Rapport's focus on precision medicines and selective targeting of RAPs could provide a competitive advantage if RAP-219 demonstrates superior efficacy and safety compared to existing treatments and competing pipeline assets.
• The cash runway through the end of 2026 is a positive sign, as many biotech companies face challenges in securing funding for their clinical programs.

Management Changes

Stakeholder Impact

• Shareholders: The positive clinical trial progress and strong cash position are likely to be viewed favorably by shareholders.
• Employees: The company's continued growth and development provide opportunities for employees.
• Patients: Successful development of RAP-219 could provide new treatment options for patients with neurological and psychiatric disorders.

Next Steps

• Advance the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy and announce topline results in the third quarter of 2025.
• Initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027.
• Finalize plans to conduct a Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) after addressing the FDA's concerns.

Key Dates